GlassScriptPhysician profile
Dan R Cimponeriu
NPI 1134133218
$5,792.71
in general payments reported to CMS, 2019-2025
25 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $179 · 2021: $1,296 · 2022: $962 · 2023: $892 · 2024: $916 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,118.17 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,168.83 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Gilead Sciences, INC. | $700.88 | 2019-2025 | |
| Janssen Biotech, INC. | $297.23 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $193.99 | 2021-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $191.70 | 2020-2024 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $179.67 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $129.89 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $116.52 | 2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $100.30 | 2021-2023 | Ocaliva |
| Celgene Corporation | $78.73 | 2024 | Zeposia |
| Cumberland Pharmaceuticals, INC. | $60.05 | 2019-2021 | |
| Pfizer INC. | $58.51 | 2019-2023 | |
| Shionogi INC | $53.23 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $51.24 | 2024 | Iqirvo, Bylvay |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $45.74 | 2021-2022 | |
| Ardelyx, INC. | $43.87 | 2023-2025 | Ibsrela |
| Capsovision, INC. | $38.27 | 2023-2024 | Capsocam Plus |
| Celltrion USA INC. | $27.44 | 2024 | Vegzelma |
| Genzyme Corporation | $25.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.50 | 2019 | |
| Novo Nordisk INC | $23.22 | 2025 | Wegovy |
| Alfasigma USA, INC. | $22.26 | 2021 | |
| Vivus LLC | $22.23 | 2024 | Qsymia |
| Madrigal Pharmaceuticals | $21.40 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Cimponeriu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.